Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 1
1983 2
1984 1
1985 4
1986 1
1987 3
1988 3
1989 3
1990 6
1991 1
1992 3
1993 10
1994 8
1995 8
1996 7
1997 2
1998 9
1999 6
2000 18
2001 14
2002 5
2003 7
2004 7
2005 8
2006 8
2007 9
2008 7
2009 6
2010 13
2011 10
2012 8
2013 13
2014 15
2015 10
2016 16
2017 15
2018 7
2019 14
2020 18
2021 29
2022 15
2023 28
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Results by year

Filters applied: . Clear all
Page 1
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Brahmer JR, Lee JS, Ciuleanu TE, Bernabe Caro R, Nishio M, Urban L, Audigier-Valette C, Lupinacci L, Sangha R, Pluzanski A, Burgers J, Mahave M, Ahmed S, Schoenfeld AJ, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Gupta RG, Bushong J, Li L, Blum SI, Eccles LJ, Ramalingam SS. Brahmer JR, et al. Among authors: urban l. J Clin Oncol. 2023 Feb 20;41(6):1200-1212. doi: 10.1200/JCO.22.01503. Epub 2022 Oct 12. J Clin Oncol. 2023. PMID: 36223558 Free PMC article. Clinical Trial.
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M, Zurawski B, Alexandru A, Vergnenegre A, Raimbourg J, Feeney K, Kim SW, Borghaei H, O'Byrne KJ, Hellmann MD, Memaj A, Nathan FE, Bushong J, Tran P, Brahmer JR, Reck M. Paz-Ares LG, et al. Among authors: urban l. J Thorac Oncol. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010. Epub 2021 Oct 12. J Thorac Oncol. 2022. PMID: 34648948 Free article. Clinical Trial.
Genomic basis for RNA alterations in cancer.
PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium. PCAWG Transcriptome Core Group, et al. Among authors: urban l. Nature. 2020 Feb;578(7793):129-136. doi: 10.1038/s41586-020-1970-0. Epub 2020 Feb 5. Nature. 2020. PMID: 32025019 Free PMC article.
Breast cancer screening.
Chala LF, Urban LABD. Chala LF, et al. Among authors: urban labd. Radiol Bras. 2023 Jul-Aug;56(4):V-VI. doi: 10.1590/0100-3984.2023.56.4e1-en. Radiol Bras. 2023. PMID: 37829579 Free PMC article. No abstract available.
Lung Cancer in Hungary.
Bogos K, Kiss Z, Gálffy G, Tamási L, Ostoros G, Müller V, Urbán L, Bittner N, Sárosi V, Vastag A, Polányi Z, Nagy-Erdei Z, Vokó Z, Nagy B, Horváth K, Rokszin G, Abonyi-Tóth Z, Barcza Z, Moldvay J. Bogos K, et al. Among authors: urban l. J Thorac Oncol. 2020 May;15(5):692-699. doi: 10.1016/j.jtho.2019.11.001. J Thorac Oncol. 2020. PMID: 32340676 Free article. No abstract available.
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.
Ready NE, Audigier-Valette C, Goldman JW, Felip E, Ciuleanu TE, Rosario García Campelo M, Jao K, Barlesi F, Bordenave S, Rijavec E, Urban L, Aucoin JS, Zannori C, Vermaelen K, Arén Frontera O, Curioni Fontecedro A, Sánchez-Gastaldo A, Juan-Vidal O, Linardou H, Poddubskaya E, Spigel DR, Ahmed S, Maio M, Li S, Chang H, Fiore J, Acevedo A, Paz-Ares L. Ready NE, et al. Among authors: urban l. J Immunother Cancer. 2023 Feb;11(2):e006127. doi: 10.1136/jitc-2022-006127. J Immunother Cancer. 2023. PMID: 36725084 Free PMC article. Clinical Trial.
Real-time genomics for One Health.
Urban L, Perlas A, Francino O, Martí-Carreras J, Muga BA, Mwangi JW, Boykin Okalebo L, Stanton JL, Black A, Waipara N, Fontsere C, Eccles D, Urel H, Reska T, Morales HE, Palmada-Flores M, Marques-Bonet T, Watsa M, Libke Z, Erkenswick G, van Oosterhout C. Urban L, et al. Mol Syst Biol. 2023 Aug 8;19(8):e11686. doi: 10.15252/msb.202311686. Epub 2023 Jun 16. Mol Syst Biol. 2023. PMID: 37325891 Free PMC article. Review.
Author Correction: Genomic basis for RNA alterations in cancer.
PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium. PCAWG Transcriptome Core Group, et al. Among authors: urban l. Nature. 2023 Feb;614(7948):E37. doi: 10.1038/s41586-022-05596-y. Nature. 2023. PMID: 36697831 Free PMC article. No abstract available.
TRPV4: Molecular Conductor of a Diverse Orchestra.
White JP, Cibelli M, Urban L, Nilius B, McGeown JG, Nagy I. White JP, et al. Among authors: urban l. Physiol Rev. 2016 Jul;96(3):911-73. doi: 10.1152/physrev.00016.2015. Physiol Rev. 2016. PMID: 27252279 Free article. Review.
Safety differentiation: emerging competitive edge in drug development.
Uteng M, Urban L, Brees D, Muller PY, Kullak-Ublick GA, Bouchard P, Tougas G, Chibout SD. Uteng M, et al. Among authors: urban l. Drug Discov Today. 2019 Jan;24(1):285-292. doi: 10.1016/j.drudis.2018.09.009. Epub 2018 Sep 19. Drug Discov Today. 2019. PMID: 30244081 Free article. Review.
361 results